Maintain status-quo on Sun Pharma-Ranbaxy merger: HC to BSE, NSE
Apr 29 2014 , Hyderabad
Based on a writ petition filed by some individual investors, the High Court while ordering the status quo on Friday, issued notices to SEBI, BSE, NSE, Sun Pharma, Ranbaxy, Daichii Sankyo and Silver Street Developers.
"There shall be interim status quo, as prayed for," Justice P Naveen Rao said his order.
The petitioners alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6, and requested the court to direct the SEBI to investigate the insider trading of Ranbaxy shares and take appropriate action against Sun Pharma and Silver Street.
The petitioners also requested the court to 'restrain' the BSE and NSE from giving any clearance to the scheme of amalgamation or merger between the two drug makers.
"However, the extensive and sudden rise in the share price of Respondent 5 (Ranbaxy) prior to announcement of merger clearly demonstrates that certain persons had prior information about the said merger. Consequently the trading on the said shares amounts to violation of SEBI Insider Trading Regulations," the petitioner alleged.
According to legal experts, both Sun Pharma and Ranbaxy will have to obtain approvals from BSE and NSE before proceeding for further clearances from various institutions such as Competition Commission of India and respective High Courts, on the merger.
Sun Pharma had earlier denied insider trading charges against Silverstreet Developers LLP - its wholly owned arm - in the USD 4 billion acquisition deal of Ranbaxy Laboratories.
In a statement, Sun Pharma had said the matter related to purchase of shares of Ranbaxy Laboratories Ltd by Silverstreet Developers LLP "does not violate insider trading rules".
As per the statement submitted to the court, more than seven million Ranbaxy shares were traded before the merger announcement was made, pushing the share price over 25 per cent.